Clover Health Investments is now a contrarian buy, with the market underestimating its path to profitability in 2026. See why I rate the CLOV stock a Buy.

Clover Health Investments is trading lower Tuesday afternoon after the Trump administration proposed flat MA payment rates for 2027.

Over the last six months, Clover Health’s shares have sunk to $2.60, producing a disappointing 13.5% loss - a stark contrast ...

Clover Health Investments Corp (NASDAQ: CLOV) stock is rising Wednesday after the company announced that it expects to ...

What Happened? Shares of health insurance company Clover Health (NASDAQ:CLOV) jumped 2.5% in the afternoon session after ...

Shares of Clover Health fell more than 8% on Thursday following a critical report from short seller Hindenburg Research claiming the company is under an active investigation by the Department of ...

Shares of Clover Health (CLOV) plunged ~20% on Wednesday following the company’s Q3 2025 results, as the health insurer sharply lowered its full-year guidance for adjusted EBITDA despite increasing ...

Clover Health Investments (CLOV) drew fresh attention after reporting a 53% year-over-year jump in Medicare Advantage PPO ...

Clover Health Investments, Corp. (CLOV) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful ...

Clover maintained stable plan benefits year-over-year, resulting in over 95% AEP member retention. More than 97% of the company’s January 1, 2026 Medicare Advantage membership is enrolled in its ...